http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#Head
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#assertion
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#provenance
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#pubinfo
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#assertion
http://purl.obolibrary.org/obo/DOID_13189
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_13189
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00437
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#association
http://www.w3.org/2000/01/rdf-schema#label
this is not an innocuous drug it is not recommended for the treatment of asymptomatic hyperuricemia allopurinol reduces serum and urinary uric acid concentrations its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics see clinical pharmacology contraindications warnings precautions allopurinol is indicated in the management of patients with signs and symptoms of primary or secondary gout acute attacks tophi joint destruction uric acid lithiasis and or nephropathy the management of patients with leukemia lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels allopurinol treatment should be discontinued when the potential for overproduction of uric acid is no longer present the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 8 mg day in male patients and 75 mg day in female patients therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#association
https://w3id.org/biolink/vocab/relation
https://w3id.org/um/neurodkg/SymptomaticReliefIndication
https://identifiers.org/drugbank:DB00437
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#provenance
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#pubinfo
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#sig
http://purl.org/nanopub/x/hasSignature
VWUN/AcNq3zQ4kcJYaq3Jt8ctCgTpRIHllQ27euKFT3FjXMbQLV9pf7CLxDfBzppV8uPZvI7RxpSQHgz4f/Rb/na2JMmFlwJdXoabvM7pPxvJOEx+oGx7Kk+bY2pQA+Yim7pzOokw8rqgIVCox6aJRuok0BnFwlpaQPIBaVokjY=
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4
http://purl.org/dc/terms/created
2021-06-13T14:45:48.675+02:00
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs